Augmedix Names Tomer Levy as New Senior Vice President of Engineering
February 13 2024 - 7:00AM
Augmedix (Nasdaq: AUGX), a healthcare technology company that
delivers industry-leading ambient medical documentation and data
solutions, today announced that Tomer Levy joined the company in
January 2024 in the newly-created Senior Vice President of
Engineering role.
Levy brings over 20 years of experience in
healthcare information technology. Throughout his career, he has
delivered innovative solutions in healthcare IT to large
enterprises worldwide.
“We are thrilled to have Tomer join Augmedix as
we continue to push the boundaries of AI-powered medical
documentation technology to alleviate administrative burden,” said
Manny Krakaris, CEO of Augmedix. “Tomer has a distinguished career
managing complex, global infrastructures, and having him on the
Augmedix team will allow us to optimize engineering performance,
streamline product development, and accelerate scalability to
health systems across the nation. Tomer's ownership of our
production systems will enable our CTO, Saurav Chatterjee, to focus
on pushing the frontiers of AI technology embedded in our
platform.”
Prior to joining Augmedix, Levy most recently
served as Senior Vice President of Research and Development at
Change Healthcare. He is passionate about the adoption of cloud
technologies that will define a new benchmark for simplicity,
cost-effectiveness, cybersecurity, and leveraging data for improved
clinical outcomes. Levy worked closely with the Google Cloud
Platform team to build a transformative cloud-native solution for
medical imaging that set a new standard for scale, reliability, and
efficiency.
“It is an exciting time to join Augmedix as the
company builds on its leadership in medical documentation and
prepares to launch new products and features in the coming months,”
said Levy. “I am looking forward to working with this impressive
team to further accelerate development and ultimately continue to
deliver on Augmedix’s mission of collaborating with hospitals and
health systems to improve clinician and patient experiences.”
Levy graduated from the executive MBA program at
Tel Aviv University and earned a bachelor’s degree in computer
science and economics.
About Augmedix
Augmedix (Nasdaq: AUGX) delivers
industry-leading, ambient medical documentation and data solutions
to healthcare systems, physician practices, hospitals, and
telemedicine practitioners.
Augmedix is on a mission to help clinicians and
patients form a human connection by seamlessly integrating our
technology at the point of care. Augmedix’s proprietary platform
digitizes natural clinician-patient conversations, which are
converted into comprehensive medical notes and structured data in
real-time. The company’s platform uses automatic speech
recognition, and natural language processing, including large
language models, to generate accurate and timely medical notes that
are transferred into the EHR.
Augmedix’s products relieve clinicians of
administrative burden, in turn, reducing burnout, increasing
clinician efficiency, and improving patient access. Through
Augmedix’s proprietary platform and bi-directional communication
channel, Augmedix is ideally suited to serve as the vehicle for
change at the point of care.
Augmedix is headquartered in San Francisco, CA,
with offices around the world. To learn more, visit
www.augmedix.com.
Contact Information
Investors:Matt Chesler, CFAFNK IR646-809-2183augx@fnkir.com
investors@augmedix.com
Media:Kaila GrafemanAugmedixpr@augmedix.com
Forward-Looking StatementsThis
press release contains "forward-looking statements" that involve a
number of risks and uncertainties. Such forward-looking statements
include, without limitation, the commitment and development of
AI-powered medical documentation technology to alleviate
administrative burden, the statement regarding Tomer Levi joining
Augmedix and the role he will play in allowing us to optimize
engineering performance, streamline product development, and
accelerate scalability to health systems across the nation, and the
launching of new products and features. Actual results could differ
materially from those stated or implied in forward-looking
statements due to a number of factors, including but not limited
to, risks detailed in our most recent Form 10-K filed with the U.S.
Securities and Exchange Commission on April 17, 2023, as well as
other documents that may be filed by us from time to time with the
U.S. Securities and Exchange Commission. The forward-looking
statements included in this press release represent our views as of
the date of this press release. We undertake no intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of
this press release.
Augmedix (NASDAQ:AUGX)
Historical Stock Chart
From May 2024 to Jun 2024
Augmedix (NASDAQ:AUGX)
Historical Stock Chart
From Jun 2023 to Jun 2024